The paperwork process will take several weeks, and the FDA’s vaccine validation advisory board meeting is scheduled for December. reports TV channel CBNC. If the manufacturers’ application is approved without delay, vaccinations could begin as early as December. The vaccination campaign will be carried out in stages, and the first to receive the drug will be medical workers and people at risk – over 65 years old and patients with chronic diseases. Teachers, homeless people and prisoners will be next. Children and young people will be the last to receive the vaccine.
Pfizer CEO Albert Bourla said the filing with the FDA marks an important milestone on the road to spreading the COVID-19 vaccine around the world.
“We now have a better understanding of the effectiveness and safety of our vaccine, which gives us confidence in its potential,” Burla said.
On November 18, Pfizer and BioNTech rated their BNT162b2 vaccine at 95% efficacy for all ages, races and ethnic groups, including seniors who are at risk. Information obtained from a final analysis of 170 confirmed cases of infection among 43,000 volunteers who received two doses of the vaccine, with 163 cases in the placebo group.
In addition, the drug helped prevent the severe course of COVID-19 in sick volunteers. During the tests, 10 such cases were registered, of which 9 were in the placebo group.
On November 16, biotech company Moderna estimated the effectiveness of its vaccine at 94.5% based on an interim analysis. It is a major competitor to Pfizer and BioNTech, as both manufacturers used mRNA technology to create the vaccine that could potentially “train” a healthy immune system to make antibodies to fight infection.